Last year, the software helped [Abbott Vascular] keep clinical trial spending within a mere 1% of target, reports Thomas Engels, director of clinical program management.

— as reported in eCliniqua
February 1, 2010
Read the full article

We performed comparisons of completed trials to what the ClearTrial system would have predicted as the total budgets. In all of these tests, the ClearTrial estimate came within 5% of our actual costs.

— Tim Hoos
Senior Director of Business Operations
Astellas Pharma Global Development

We are looking forward to utilizing the capabilities of ClearTrial, to allow us to quickly compare cost scenarios for different approaches—fully outsourced, outsourced by function, independent contractors, and studies performed in whole or in part by internal Cubist personnel.

— Dr. Santosh Vetticaden
Chief Medical Officer
Cubist Pharmaceuticals

Underlying country-specific metrics about timelines, costs, and currency exchange rates also streamlined [Abbott Vascular's] first-ever negotiations with Chinese service providers.

— as reported in eCliniqua
February 1, 2010
Read the full article